Artrya Limited (AU:AYA)
ASX:AYA
AYA Stock Chart & Stats
AU$3.13
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$3.13
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.57 - AU$5.24
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$494.80M
Enterprise ValueAU$356.88M
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding158,084,010
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.27Price Target Upside100.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$10.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and an improving debt-to-equity ratio provide greater financial runway and lower refinancing risk, enabling Artrya to continue R&D and commercialization efforts without near-term solvency pressure. This structural balance-sheet strength supports strategic flexibility over months.
Early Revenue TractionRecording initial revenue in FY2025 signals early commercial validation of Artrya’s product and the start of a revenue base. While small, this demonstrates the company can convert trials into paying customers, an essential step toward repeatable, scalable revenue over the next several quarters.
Structural AI Imaging TailwindsArtrya operates in AI-driven cardiovascular imaging, a durable sector with rising clinical demand for decision-support tools. Structural digitization and clinician interest in diagnostic analytics give the company a meaningful addressable market and potential for recurring software/licensing revenue streams.
Bears Say
High Cash BurnSustained negative operating and free cash flow at this magnitude requires ongoing external financing or material margin improvement. Persistent cash burn constrains strategic options, raises dilution risk for shareholders, and makes execution on commercialization dependent on successful capital raises within months.
Persistent Unprofitable OperationsThe company has not demonstrated operating leverage or path to breakeven, with consistently negative margins. Without clear margin improvement or scaling of revenue, profitability remains uncertain, making long-term viability dependent on either rapid revenue growth or material cost reductions.
Declining Equity And Negative ROEDeclining shareholder equity and sharply negative ROE indicate ongoing value erosion from losses. This weakens the capital buffer available for investment and increases vulnerability to future shocks, reducing resilience and potentially complicating fundraising or strategic partnerships.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.57 and its highest was AU$5.24 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$494.80M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 141 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.085.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 158,084,010 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.27 (100.32% Upside)
AU$6.27 (100.32% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-35.63%
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.27
▲(100.32% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―